Réaction #640527

ord-dde274e722b0409d87706d81630193ab

Équation de réaction

N#CCCNc1nonc1-c1nc2ccccc2[nH]1
4-(1H-benzimidazol-2-yl)-furazan-3-yl-N-(2-cyanoethyl)-amine
N#CCCNc1nonc1-c1nc2ccccc2[nH]1
4-(1H-Benzimidazol-2-yl)-furazan-3-yl-N-(2-cyanoethyl)-amine
[Al+3].[H-].[H-].[H-].[H-].[Li+]
LiAlH4
C1CCOC1
THF
C1CCOC1
THF
OCCCNc1nonc1-c1nc2ccccc2[nH]1
title compound
OCCCNc1nonc1-c1nc2ccccc2[nH]1
4-(1H-Benzimidazol-2-yl)-furazan-3-yl-N-(3-hydroxypropyl)-amine

Conditions de réaction

Conditions détaillées
See reaction.notes.procedure_details.

Traitement

  1. 1
    Autreis quenched by careful addition of aqueous saturated solution of sodium sulphate
  2. 2
    FiltrationThe suspension is filtered
  3. 3
    Autrethe filtrate evaporated to dryness
  4. 4
    AutreCrystallization
  5. 5
    workup.ADDITIONby addition of hexane

Mode opératoire

A solution of 4-(1H-benzimidazol-2-yl)-furazan-3-yl-N-(2-cyanoethyl)-amine (0.272 g, 0.947 mmol, Example 6a) in THF (5 ml) is added dropwise at 0° C. to an efficiently stirred suspension of LiAlH4 (0.054 g, 1.42 mmol) in THF (5 ml). After stirring for 16 hours at room temperature the mixture is quenched by careful addition of aqueous saturated solution of sodium sulphate. The suspension is filtered and the filtrate evaporated to dryness. Crystallization by addition of hexane yields the title compound in pure form. 1H-NMR (400 MHz, d6-DMSO): 13.6 (s, 1H); 7.66 (m, 2H); 7.31 (m, 2H); 6.92 (t, 1H); 4.61 (m, 1H); 3.51 (m, 2H); 3.39 (m, 2H); 1.81 (m, 2H).

Source

DOI: 10.6084/m9.figshare.5104873.v1Brevet: USRE042890E1uspto-grants-2011_11